POP Flashcards
What types of POP are available? (4)
- Desogestrel (DSG) 75mcg
- Levonorgestrel (LNG) 30mcg
- Norethisterone (NET) 250mg
Coming soon: 4. Drospirenone (DRSP) 4mcg
How is the POP taken?
Continuously at 24h intervals without HFI
Apart from the new pill drospirenone which has 4 HFI days. Some will have a bleed.
How do the POPs prevent pregnancy?
Desogestrel and drospirenone (the D’s) inhibit ovulation.
Levonorgestrel & norethisterone (the “traditional” POPs) do not reliably inhibit ovulation, they rely for contraceptive effectiveness on their effect on cervical mucus, endometrium and tubal motility.
Age limitations POP
All POPs can be used between menarche and age 55 in medically eligible individuals
What UKMEC is it for POPs for those individuals with a history of ectopic pregnancy and ovarian cysts?
1
List the UKMEC 3’s for the POPs
UKMEC 3
- Current and history of ischaemic heart disease (UKMEC 2 for initiation, UKMEC 3 for continuation) [UKMEC 4 in CHC]
- History of stroke (UKMEC 2 for initiation, UKMEC 3 for continuation) [UKMEC 4 in CHC]
- Past breast cancer [UKMEC 3 in CHC]
- Severe (decompensated) cirrhosis (associated e.g. with ascites, jaundice, encephalopathy or GI haemorrhage) [UKMEC 4 in CHC]
- Hepatocellular adenoma or carcinoma [UKMEC 4 in CHC]
List the UKMEC 4’s for the POPs
- Current breast cancer
NB. For individuals with a history of breast cancer, any decision to initiate hormonal contraception may be best made in consultation with their oncology team.
How does the new POP drospirenone work? What is the risk of this.
It is a potent progestogen with a similar pharmacological profile to progesterone. A spironolactone derivative [aldosterone antagonist], it has anti-mineralocorticoid and mild anti-androgenic activity. Drospirenone is an aldosterone antagonist thus there is a risk of hyperkalaemia in susceptible individuals.
Who should drospirenone not be used by?
Patients:
- with severe renal insufficiency or acute renal failure
- with known hyperkalaemia or untreated hypoaldosteronism (e.g. Addison’s)
- using K sparing diuretics, aldosterone antagonists or K supplements
Who should drospirenone be used with caution by?
Patients:
- with mild/ moderate renal insufficiency
- with treated hypoaldosteronism (e.g. treated Addison’s)
- using ACEi’s and ARBs
What investigations might be considered before starting drospirenone and in who?
U+Es & BP
In those who have risk factors for CKD e.g. HTN, CVD, DM, particularly if over 50
How effective is the POP?
- Contraceptive effectiveness of the POP relies on correct use
- If used perfectly, POPs may be more than 99% effective
- Estimated typical failure rate is about 9%
What potential drug interactions are there?
- POP effectiveness reduced during use of the enzyme-inducer and for 28 days after stopping the enzyme-inducer. Offer alternatives: DMPA, the Cu-IUD or the LNG-IUS are suitable options if the individual is medically eligible.
- POP could reduce effectiveness of UPA for EC. The ability of UPA-EC to delay ovulation could be reduced if a POP is started within 5 days of taking the UPA. The ability of UPA-EC to delay ovulation could theoretically be reduced if a POP has been taken in the preceding 7 days. Advise use condoms for 5d after UPA + 2 days while POP takes effect (7d for drospirenone)
Weight / BMI with POP
Contraceptive effectiveness not affected by body weight or BMI
What could effect the absorption of POP
Vomitting
Severe diarrhoea
Bariatric surgery